EAU 2020: Late Toxicity and Quality of Life from GETUG-AFU 22 Study: A Randomised Phase II Trial Comparing 6 Months of Degarelix in Combination with Radiotherapy to Radiotherapy Alone for Patients with Detectable PSA After Radical Prostatectomy

(UroToday.com) The best abstract oncology session at the virtual EAU 2020 meeting featured second place winner Dr. Paul Sargos discussing late toxicity and quality of life from the GETUG-AFU 22 study. Currently, no recommendations exist for patients with immediate detectable prostate specific antigen (PSA) after radical prostatectomy. The purpose of the GETUG-AFU 22 study was to compare the toxicity and quality of life results in adding hormone therapy to radiotherapy for patients with detectable PSA after radical prostatectomy.